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An interesting approach has been proposed to diﬀerentiate malignant glioneuronal tumors (MGNTs) as a subclass of the WHO
grade III and IV malignant gliomas. MGNT histologically resemble any WHO grade III or IV glioma but have a diﬀerent
biological behavior, presenting a survival twice longer as WHO glioblastomas and a lower occurrence of metastases. However,
neurofilament protein immunostaining was required for identification of MGNT. Using two complementary methods, dynamic
contrast-enhancedmagnetic resonance imaging (DCE-MRI) and texture analysis (MRI-TA) from the same acquisition process, the
challenge is to in vivo identify MGNT and demonstrate that MRI postprocessing could contribute to a better typing and grading
of glioblastoma. Results are obtained on a preliminary group of 19 patients a posteriori selected for a blind investigation of DCE
T1-weighted and TA at 1.5 T. The optimal classification (0/11 misclassified MGNT) is obtained by combining the two methods,
DCE-MRI and MRI-TA.
1. Introduction
Glioblastomas represent the majority of the glial tumors, but
their phenotypic and genotypic heterogeneities are large, as
attested by the appellation “glioblastoma multiforme”. Their
World Health Organization (WHO) classification is mainly
based on histological criteria. As the result of a consensus, the
classification associates several concepts that are discussed
and debated. New approaches of malignant gliomas grading
are requested for treatment individualization as well as for
the development of new drugs and treatment strategies.
An interesting approach has been proposed by Saint-
Anne Hospital (Paris) to diﬀerentiate malignant glioneu-
ronal tumors (MGNTs) from WHO grade III and IV malig-
nant gliomas: in a previous study concerning 49 patients
classified as WHO grade IV, 10 have been identified as
MGNT with a survival twice longer as glioblastomas and a
lower occurrence of metastases. Gross total surgical resection
may be curative in some cases [1–3]. Though MGNT
histologically resemble anyWHOgrade III or IV glioma, they
have a diﬀerent biological behavior. Neurofilament protein
(NFP) immunostaining is strictly required for identification
of MGNT by pathologist [3] and has been considered as the
gold standard for this study even if it is not the only one
discriminant parameter taken into account by pathologists.
Compared to histology or molecular biology, mag-
netic resonance imaging: (i) associates a large range of
complementary acquisition and postprocessing modalities
as, for instance, diﬀusion weighted imaging (DWI) or
susceptibility-weighted imaging (SWI), dynamic contrast-
enhanced (DCE) MRI or texture analysis (MRI-TA) [4–
8], (ii) is performed in vivo and then could contribute to
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early diagnosis and treatment followup, and (iii) allows the
mapping of intra or peritumoral heterogeneity which is a
highly diﬃcult challenge when analysing biopsies or surgical
pieces. Even if genomics and proteomics will probably be
in a near future the gold standard for tumor subtyping,
our challenge, on the basis of the example of MGNT,
was to illustrate a potential important contribution from
presurgical functional MRI data.
Using two complementary methods on the same set of
MR images, a static one (MRI-TA) and a dynamic one (DCE-
MRI), the challenge was to in vivo characterize the subclass
of MGNT and to demonstrate that MRI could usefully
contribute to revisit the malignant glioma typing even if
an early typing of these tumors do not modify the surgery
strategy.
2. Patients andMethods
2.1. Patients. Nineteen patients (9 female and 10 male
patients; median age, 57 years; range 40–71 years) with grade
IV gliomas according to theWHO classification were selected
a posteriori for this study: 8 Glioblastoma (GBM) and 11
MGNT according to the Saint-Anne classification.
2.2. Pathology. All patients underwent a subtotal or a gross
total resection, and a single experienced neuropathologist
reviewed histological specimens. The evaluated histological
parameters included necrosis, vascular proliferation, mitosis,
presence of giant cells and cell, density. Tumor necrosis
was recorded as present when observed in at least one
area in the total histological samples available. Percentage
of necrosis was estimated by analysis of the totality of the
paraﬃn-embedded tissue. Vascular proliferation was noted
as low rate when endothelial cells begin confluence and
as high rate when glomeruloid aspects were noted. Mitosis
was analyzed in the most mitotically active tumoral area
by counting number of mitosis per 10 contiguous high-
power magnification fields. Cellularity was defined as low,
moderate or high, according to the presence or absence of
neuropil between tumor cells. For each case, perivascular
lymphocytes, multinucleated giant cells, and dense reticulin
network were noted when present.
Systematic immunohistochemistry study was performed
for all cases on representative paraﬃn-embedded tumoral
tissue with glial fibrillary acidic protein (GFAP) (clone 6F2)
and neurofilament (clone 2F11). When at least one tumoral
cell exhibited a positive labelling for neurofilament, case was
considered as a MGNT, in agreement with the Saint-Anne
protocol.
As neurofilament is rather heterogeneous inducing po-
tential diagnosis error related to sampling for pathology
examination, we have considered as MGNT all tumors
exhibiting at least one cell with positive labeling for neuro-
filament. MGNT diagnosis also includes other information
but, according to [3], we have considered that this criteria
could be at this time used as the gold standard for this study.
2.3. Dynamic MRI Acquisition and Longitudinal Relaxation
Rate Measurements. 2D MRI serial acquisitions were per-
formed with a head coil on a 1.5 T imager (GE Signa,
Milwaukee, USA). The quantitative MR Imaging protocol
has been adapted from previously published studies [9,
10]. 2D fast multiplanar spoiled gradient echo (FMPSPGR)
sequences (TR/TE = 150/5.6ms and variable flip angle, θ1 =
10◦, θ2 = 90◦) were performed. Thirteen sagittal slices
were acquired with a field of view of 180mm × 240mm, a
slice thickness of 5mm, and a 192 × 256 matrix leading to
spatial resolution of 0.94mm × 0.94mm. Five longitudinal
relaxation time (T1) calibration vials (T1 ranging from
120ms to 2174ms at 1.5 T and 19◦C) were positioned in
the coil and simultaneously imaged with the patient. For
parameter extraction, regions of interest (ROI) including
about 1500 pixels were manually positioned on the tumor
and on the calibration vials on postcontrast images and
on the corresponding part of the precontrast image. Before
contrast injection, the initial longitudinal relaxation rate R10
value of each ROI was obtained with the two images acquired
with the 2 diﬀerent flip angles (θ1 = 10◦, θ2 = 90◦). After
a bolus injection of a 0.1mmol·Kg−1 dose of Gd-DOTA
(DOTAREM, Guerbet, France), the dynamic relaxometry
curves were recorded during 15 minutes. In order to increase
temporal resolution, only one T1 weighted acquisition with
a θ2 = 90◦ flip angle was performed for each measurement.
Indeed, for small flip angles the signal is independent on R1
and does not change after gadolinium injection. For each set
of images, the temporal resolution was 28 seconds.
2.4. Physiological Parameters Extraction from DCE-MRI.
Postprocessing of DCE-MRI was done with tools developed
for ImageJ (ImageJ, Rasband, W.S., US National Institutes of
Health, Bethesda, MD, USA http://rsb.info.nih.gov/ij/, 1997–
2011) and IDL 5.2 (Research System Incorporation, Boulder,
CO, USA). After injection of a bolus D (mmol·kg−1) of
Gd-DOTA, which distributes in the extracellular space, the
relaxation rate of the tissue at time t after the injection is
R1(t) = R10 + rveCEES(t), (1)
where r (mmol·s−1) is the relaxivity of the extracellular fluid,
CEES the contrast agent concentration in the extravascular
extracellular space (EES) at time t, R10 (s−1) the relaxation
rate before contrast injection, and R1(t) (s−1) the relaxation
rate after contrast injection.
At time t after contrast injection, the plasma concentra-
tion is given by the exponential relation(6)
Cp(t) = D ·
∑
i=1,2ai · e−mit, (2)
ai andmi are plasmatic constants describing the early mixing
phase (i = 1) and the later extraction phase (i = 2). On
the Basis of Weinmann et al. data [11], Tofts and Kermode
established that for Gd-DTPA a1 = 3, 99 kg·l−1, a2 =
4.78 kg·l−1, m1 = 0.144min−1, and m2 = 0.011min−1. By
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Table 1: MRI and pathology data (pathology).
Patient n◦
Neurofilament
immunostaining
a
N of mitosis
(in 10 areas)
Vascular
proliferation
Cell density Giant cells
Other WHO
Glioblastomas
P02 − 50 12 + + −
P09 − 35 6 + + +
P26 − 50 12 + + −
P29 − 70 5 + + +
P31 − 30 36 + + −
P41 − 80 65 + + −
P42 − 60 31 + ± +
P53 − 20 12 + + −
GBM 8/8  49, 38± 20, 43 22, 38± 20, 60 8/8⊕ 7/8⊕
1/8
3/8⊕
5/8 
MGNT
P01 + 20 30 + ± +
P18 + 60 40 + + +
P20 + 35 48 + + +
P22 + 20 36 + + −
P23 + 40 11 + + −
P36 + 20 5 + ± +
P43 + 50 3 + ± −
P47 + 50 4 + ± −
P48 + 50 10 + ± −
P51 + 40 17 + + +
P52 + 35 21 + + −
MGNT 11/11⊕ 38, 18± 13, 83 20, 45± 15, 81 11/11⊕ 6/11⊕
5/11
5/11⊕
6/11 
using the model described by Tofts and Kermode [12], the
contrast agent concentration in EES is
CEES(t) = K
trans
ve
·
∑
i=1,2
ai ·
(
e−(K trans/ve)t − e−mit
)
mi − (K trans/ve) , (3)
K trans (min−1) is the transfer constant which characterizes
the blood-tissue exchange processes. From (1) and (3), we
obtain
ΔR1(t) = R1(t)− R10
= K trans · r ·
∑
i=1,2
ai ·
(
e−(K trans/ve)t − e−mit
)
mi − (K trans/ve) ,
(4)
K trans and ve are calculated by fitting the experimental data
on (4) using the Levenberg-Marquadt nonlinear regression
method. In addition to transfer constant (K trans min−1) and
EES fraction ve, the following parameters were computed
from the fitted ΔR1(t) curves: maximum relaxation rate
(ΔR1max s−1), time to peak (TTP s), and slopes at 30 s (s30
s−2).
2.5. MRI Texture Analysis. On each tumor, one Region Of
Interest (ROI) of around 1500 pixels was selected by the
radiologist. Mazda imaging analysis software (Institute of
Electronics, Technical University of Lodz, Poland, version
3.20 http://www.eletel.p.lodz.pl/programy/mazda/) was used
for texture parameters calculation in ROIs. Three statis-
tical methods of TA were applied giving diﬀerent texture
parameters: (i) gray level histogram (GLH) parameters
(mean, variance, skewness, kurtosis, and percentiles) that
provide statistics on signal intensity distribution, (ii) co-
occurrence matrix (COM) parameters (e.g., entropy, energy,
correlation, contrast, inverse diﬀerence moment, etc.); this
matrix provides statistics on the joint gray-level relationships
by evaluating the probability that a gray level i occurs, at
a distance d and angle θ, from another gray level j in the
image, thus evaluating image homogeneity, directionality
and internal arrangement, and (iii) the run-length distribu-
tion matrix (RLM) parameters (gray level distribution, run-
length distribution, run percentage, etc.); these parameters
describe mainly the coarseness of the image. A “run” is
defined as a sequence of identical gray level values in a certain
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Table 3: Positive predictive value, negative predictive value, sensitivity and specificity (in %) obtained from hierarchical ascendant classifica-
tion of both MRI-texture analysis run length matrix parameters (RLM) and co-occurrence matrix parameters (COM) and dynamic contrast
enhancement MRI parameters for in vivo discrimination of MGNT from glioblastoma type.
Positive predictive value Negative predictive value Sensitivity Specificity
MRI-TA RLM 58 43 64 37
MRI-TA COM 75 71 82 62
DCE-MRI 71 80 64 50
MRI-TA COM + DCE-MRI 79 100 100 62
direction. This method calculates the probability function
p(i,d) in which each gray level i has a run of length d. Further
details of these methods can be found in [13].
2.6. Statistical Analysis. The Mann-Whitney test was used
for the estimation of statistical significance of imaging
parameters. A P value less than 0.05 was considered as statis-
tically significant. Principal component analysis (PCA) and
hierarchical ascendant classification (HAC) were performed
for each class of TA parameters and for parameters from
DCE-MRI. Analysis were performed with Xlstat (Addinsoft,
Paris, France). Positive predictive value (PPV), negative
predictive value (NPV), sensitivity, and specificity have been
calculated from HAC.
3. Results
3.1. Pathology. All tumors exhibited GFAP expressing cells
with great variation in tumor areas. Neurofilament positive
tumor cells were present in 11 cases. These tumoral cells
were cytologically indistinct from other tumor cells with
great variation in their number between the diﬀerent cases.
All tumors exhibited marked nuclear atypia and high rate
of vascular proliferation. Mitosis were present in all cases
with a mean of 25 mitosis/10 HPF for GBM group and 21
mitosis/10 HPF for MGNT group. Tumoral necrosis was
noted in all cases with a mean of 50% for GBM group and
38% for MGNT group. Only one GBM displayed moderate
cellular density (12%), other cases presenting a high cellular
density. In MGNT group, 5 cases were moderately cellular
(45%). Numerous multinucleated giant cells were observed
in 2 GBM (25%) and in 5 MGNT (45%). Accentuation
of the reticulin network was always noted and lymphocytic
perivascular cuﬃng was seen in 2 GBM (25%) and 7 MGNT
(63%) (Tables 1 and 2).
3.2. MRI Visual Examination. Visual examination of MR
images by the neuroradiologist before and after contrast
agent does not discriminate MGNT. The two expected
MRI morphological signs for MGNT characterization,
meningotropism in MGNT and ring structure in other
WHO glioblastomas, are not significant (Tables 1 and 2).
However, Figure 1 shows typical well delimited ring pattern
of GBM and a more complex “grape-like” appearance of the
presented MGNT.
3.3. DCE-MRI. Parameters describing enhancement curve
and physiological parameters have been calculated for each
patient (Tables 1 and 2). These parameters can be presented
as physiological maps (Figure 1).
3.4. Texture Analysis. Parameters from the GLH, COM, and
RLM were extracted from postinjection T1 weighted images
(Tables 1 and 2).
3.5. Statistical Analysis. Using independently the two meth-
ods, MRI-TA and DCE-MRI, a rather poor discrimination
between GBM and MGNT is obtained. Although higher
values of K trans and s30 are observed for MGNT, there are
no statistical significant diﬀerences for DCE-MRI related
parameters. From the best selected TA features horizontal
run length nonuniformity (hRLN) and horizontal grey level
nonuniformity (hGLN) from the run length matrix method
present a statistical significant diﬀerence between MGNT
and GBM with P values, respectively, P = 0.008 and P =
0.017. When associating both MRI-TA and DCE-MRI, 45%
of the information is given by the 3 first factorial axis
which are mainly weighted by hRLN, hGLN and by angular
second moment (ASM), sum entropy and entropy from the
cooccurrence matrix method. 11/11 correct classification of
MGNT is obtained (Table 3) with a positive predictive value
of 79%, a negative predictive value of 100%, a sensitivity of
100%, and a specificity of 62%.
4. Discussion
Though DCE-MRI has already been used in neuro-oncology,
previous results have mainly concerned low versus high
WHO grades [14–16] and have not revisited the WHO
grading of malignant gliomas. Also, MRI texture analysis
has opened exciting perspectives in the evaluation of intra-,
peri-, and extratumoral heterogeneity but has not been
already oriented to an attempt of malignant gliomas sub-
grading [4, 5].
This study associating DCE and TA is, at our knowledge,
the first attempt to in vivo indentify the subclass of MGNT
from glioblastoma. Associating DCE-MRI and MRI-TA, a
sensitivity of 100% and a specificity of 62% have been
obtained in the limited population already studied. The
rather low specificity may be improved by adding texture
parameters from T2 and/or diﬀusion weighted images as well
as by 3D TA approaches. This preliminary result suggests
that in vivo MRI associated with appropriate postprocessing
methods could characterize MGNT up to now identified by
ex vivo immunostaining histology. One important parameter
in pathology typing of MGNT is the angiogenic status,
well expressed by the K trans parameter in DCE MRI. It has
6 Neurology Research International
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Figure 1: From top to bottom T1-weighted MR image before and 3min after contrast agent injection, calculated map of transfer constant
(K trans in min−1) and of extracellular extravascular space fraction (ve in %). An example of a malignant glioneuronal tumor is on the left and
of a glioblastoma is on the right. The color code increases from purple to red. On the postcontrast T1 images the MGNT shows a complex
structure, whereas the GBM sows a typical enhanced ring.
also to be noticed that the relevant MRI-TA parameters are
second order parameters, then not detected by the visual
observation of the radiologist who only can detect first order
texture. Concerning other WHO high-grade gliomas, it has
to be noticed a large heterogeneity concerning these DCE-
MRI and MRI-TA parameters, suggesting again the clinical
interest of tumor individualization.
5. Conclusion
These preliminary results show the potential interest of DCE-
MRI and MRI-TA association for in vivo tumor characteri-
zation, an exciting challenge for subtyping of glioblastoma.
Furthermore, if associated with molecular tumor charac-
terization by genomics or proteomics, functional imaging
has the potential to provide additional information on
tumor heterogeneity, a highly relevant parameter for tumor
grading.
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